Aims/hypothesis:
Impaired fibrinolytic system capacity secondary to increased plasminogen activator inhibitor type-1 expression has been suggested
as a pathogenetic link between insulin resistance and increased cardiovascular risk in patients with Type II (non-insulin-dependent)
diabetes mellitus, obesity, or both. In patients with syndromes of insulin resistance including those with Type II diabetes,
precursors of insulin such as proinsulin can constitute more than 50 % of insulin-like molecules in blood. The aim of this
study was to determine whether proinsulin can increase plasminogen activator inhibitor type-1 expression in intra-abdominal
adipose tissue in vivo, potentially contributing to the increased PAI-1 seen with insulin resistance.
Methods:
Lightly sedated normal rabbits were given intravenous proinsulin, insulin, or vehicle alone under euglycaemic clamp conditions
with serial sampling of blood and assessment of PAI-1 expression in visceral fat.
Results:
Both proinsulin and insulin increased expression of plasminogen activator inhibitor type-1 in intra-abdominal adipose tissue,
5.3-fold (p = 0.006 vs control) and 2.5-fold (p = 0.031 vs control) respectively. PAI-1 inhibitor activity in blood peaked 3 h after administration of each, 5.1-fold, p = 0.020, and 3.4-fold, p = 0.004, respectively but did not change under control conditions.
Conclusion/interpretation:
Hyperproinsulinaemia can contribute to increased expression of plasminogen activator inhibitor type-1 in intra-abdominal
adipose tissue implicated in increasing PAI-1 activity in blood, impaired fibrinolysis, and accelerated atherogenesis typical
of Type II diabetes. [Diabetologia (2001) 44: 1121–1124]
Keywords Diabetes mellitus, obesity, insulin, plasminogen activators, atherosclerosis.
Received: 21 March 2001 and in revised form: 21 May 2001